Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Montelukast sodium in inhibiting infection of Zika virus, dengue virus and yellow fever virus

A technology of yellow fever virus and montelukast sodium, which is applied in the field of biotechnology and biomedicine, and can solve problems such as drugs that have not yet been developed with specific effects

Inactive Publication Date: 2017-07-28
SHANGHAI PUBLIC HEALTH CLINICAL CENT
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, there is currently no effective vaccine or drug for the prevention and / or treatment of ZIKV and DENV infection in the world
Although a vaccine has been developed against YFV infection, no specific drug has yet been developed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Montelukast sodium in inhibiting infection of Zika virus, dengue virus and yellow fever virus
  • Application of Montelukast sodium in inhibiting infection of Zika virus, dengue virus and yellow fever virus
  • Application of Montelukast sodium in inhibiting infection of Zika virus, dengue virus and yellow fever virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1. Inhibition of ZIKV, DENV and YFV infection by montelukast sodium in vitro

[0055] The experimental operation of montelukast sodium inhibition of ZIKV, DENV and YFV infection can refer to: Zhiwu Sun, et al., Intranasal Administration of Maleic Anhydride-Modified Human SerumAlbumin for Pre-Exposure Prophylaxis of Respiratory Syncytial VirusInfection; Viruses 2015,7,798-819 ;doi:10.3390 / v7020798, as follows:

[0056] (1) ZIKV, DENV and YFV were amplified by inoculating C6 / 36 cells respectively (refer to SciChina LifeSci, doi: 10.1007 / s11427-016-5043-4).

[0057] (2) Use serum-free DMEM to serially dilute Montelukast sodium in a 96-well plate to the concentrations of 80 μM, 40 μM, 20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μM, and 0.625 μM, respectively. 50 μL, 3 replicates for each concentration.

[0058] (3) Dilute ZIKV (strains SZ01, MR766, FLR), DENV-2 or YFV-17D with serum-free DMEM so that the final concentration of the virus is 100 TCID50 (half the tissue culture...

Embodiment 2

[0068] Example 2. Inhibition of HCoV-OC43 and HCoV-229E infection by montelukast sodium in vitro

[0069] (1) The human coronavirus strains HCoV-OC43 (100TCID50) and HCoV-229E (500TCID50) were respectively mixed with the serially diluted montelukast sodium prepared in Example 1, and the resulting mixture was placed in 37 Incubate at °C for 30 minutes.

[0070] (2) The mixture of HCoV-OC43 and montelukast sodium was added to a 96-well plate with a monolayer of HCT-8 cells, and the mixture of HCoV-229E and montelukast sodium was added to a monolayer of Huh7 cells. In a 96-well plate, 3 replicates were set for each concentration. The 96-well plate was incubated at 33°C (HCoV-OC43) or 32°C (HCoV-229E) for 2 hours, after which the medium was replaced with fresh medium.

[0071] (3) When the cells in the positive group showed obvious CPE (cytopathic effect), CCK8 was used to detect the inhibitory activity of montelukast sodium on the virus. For the specific operation of CCK8 detec...

Embodiment 3

[0073] Embodiment 3 Toxicity detection of montelukast sodium on BHK21 cells

[0074] The toxicity detection operation of montelukast sodium on BHK21 cells can refer to: Zhiwu Sun, et al., Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection. Viruses2015,7,798-819; doi :10.3390 / v7020798), as follows:

[0075] (1) Dilute montelukast sodium with serum-free DMEM to the concentrations of 40 μM, 20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μM, 0.625 μM, and 0.3125 μM, respectively. The dosage volume per well is 100 μL, and each concentration is 100 μL. Set 2 repetitions.

[0076] (2) BHK21 cells were digested with EDTA-EGTA digestion solution, and the cells were diluted to 4*10 with DMEM containing 2% FBS 5 / mL, and added 100 μL / well to the 96-well plate in (1). Then at 37°C, 5% CO 2 cultured for 4 days.

[0077] (3) Carefully aspirate and discard the medium in the 96-well plate, add fresh DMEM cont...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biomedicines and in particular to a small molecular drug capable of inhibiting infection of Zika virus, dengue virus and / or yellow fever virus and an application thereof. In particular, the invention relates to a method of inhibiting infection of Zika virus, dengue virus and / or yellow fever virus by Montelukast sodium and an application of Montelukast sodium in preparing a drug for preventing and / or treating related symptoms or diseases of infection of Zika virus, dengue virus and / or yellow fever virus.

Description

technical field [0001] The invention belongs to the technical fields of biotechnology and biomedicine, and in particular relates to a small molecule drug which can be used to inhibit infection of Zika virus, dengue virus and yellow fever virus and its application. Background technique [0002] Zika virus (ZIKV), dengue virus (DENV) and yellow fever virus (Yellow fever virus, YFV) all belong to the Flaviviridae genus, and are icosahedral viruses with envelope proteins. Their genome is a positive single-stranded RNA with a total of about 10800 nucleotides, encoding 3 structural proteins (PrM, Env, Capsid) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). [0003] Taking the recently popular ZIKV as an example, ZIKV is one of the arboviruses, which is mainly transmitted by the bite of Aedes mosquitoes that are active during the day, but its transmission methods include vertical mother-to-child transmission, sexual transmission and blood transfusion tra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/47A61P31/14
CPCA61K31/47A61K45/06Y02A50/30
Inventor 邹鹏陆路姜世勃
Owner SHANGHAI PUBLIC HEALTH CLINICAL CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com